Determinants of renal tissue hypoxia in a rat model of polycystic kidney disease

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 307, Issue 10, 2014, Pages R1207-R1215

  Ow, Connie P C ^a   Abdelkader, Amany ^a   Hilliard, Lucinda M ^a   Phillips, Jacqueline K ^b   Evans, Roger G ^a  

^a MONASH UNIVERSITY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

Anoxia; Chronic kidney disease; Ischemia; Oxygen; Oxygen consumption; Oxygen delivery; Renal circulation

Indexed keywords

CREATININE; HEMOGLOBIN; OXYGEN; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD OXYGENATION; CONTROLLED STUDY; CORE TEMPERATURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; ELECTRODE; EXPERIMENTAL HYPOXIA; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HYPOXEMIA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; LEWIS RAT; LPK RAT; MALE; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; OXYGEN CONCENTRATION; OXYGEN CONSUMPTION; OXYGEN TENSION; PARENCHYMA; PRIORITY JOURNAL; PULSE PRESSURE; RAT; SODIUM ABSORPTION; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TISSUE OXYGENATION; ANIMAL; ANOXIA; BLOOD; CELL HYPOXIA; DISEASE MODEL; GENETICS; HEMODYNAMICS; KIDNEY; KIDNEY CIRCULATION; KIDNEY TUBULE ABSORPTION; METABOLISM; PATHOPHYSIOLOGY; PRESSURE; VASCULARIZATION;

ANIMALS; ANOXIA; CELL HYPOXIA; DISEASE MODELS, ANIMAL; HEMODYNAMICS; KIDNEY; MALE; OXYGEN; OXYGEN CONSUMPTION; PARTIAL PRESSURE; POLYCYSTIC KIDNEY DISEASES; RATS, INBRED LEW; RENAL CIRCULATION; RENAL REABSORPTION; SODIUM;

EID: 84922393744     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00202.2014     Document Type: Article

References (56)

1. Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transpl 22: 2900-2908, 2007.
2. Belibi F, Zafar I, Ravichandran K, Segvic A, Jani A, Ljubanovic D, Edelstein C. Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol 300: F1235-F1243, 2011.
3. Bello Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomaldominant polycystic kidney disease. Kidney Int 60: 37-45, 2001.
4. Bernhardt W, Wiesener M, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong ACM, Willam C, Gretz N, Eckardt KU. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 170: 830-842, 2007.
5. Buchholz B, Schley G, Faria D, Kroening S, Willam C, Schreiber R, Klanke B, Burzlaff N, Jantsch J, Kunzelmann K, Eckardt KU. Hypoxia- inducible factor-1α causes renal cyst expansion through calciumactivated chloride secretion. J Am Soc Nephrol 25: 1-10, 2014.
6. Chauveau D, Duvic C, Chretien Y, Paraf F, CDroz D, Melki P, Helenon O, Richard S, Grunfeld JP. Renal involvement in von Hippel- Lindau disease. Kidney Int 50: 944-951, 1996.
7. Darling IM, Morris ME. Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion. Pharm Res 8: 1318-1322, 1991.
8. de Almeida EAF, Alho I, Marques F, Thiran C, Bicho MP, Prata M. Haemoglobin and erythropoietin levels in polycystic kidney disease. Nephrol Dial Transplant 23: 412-413, 2008.
9. Deltas C, Papagregoriou G. Cystic diseases of the kidney. Molecular biology genetics. Arch Pathol Lab Med 134: 569-582, 2010.
10. Ding A, Kalaignasundaram P, Ricardo SD, Abdelkader A, Witting PK, Broughton BRS, Kim HB, Wyse BF, Phillips JK, Evans RG. Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease. Clin Exp Pharmacol Physiol 39: 917-929, 2012.
11. Eckardt KU, Mollmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U. Erythropoietin in polycystic kidneys. J Clin Invest 84: 1160-1166, 1989.
12. Edlund J, Fasching A, Liss P, Hansell P, Palm F. The roles of NADPH-oxidase and nNOS for the increased oxidative stress and the oxygen consumption in the diabetic kidney. Diabetes Metab Res Rev 26: 349-356, 2010.
13. Evans RG, Gardiner BS, Smith DW, O'Connor PM. Methods for studying the physiology of kidney oxygenation. Clin Exp Pharmacol Physiol 35: 1405-1412, 2008.
14. +reabsorption. Am J Physiol Renal Physiol 306: F551-F560, 2014.
15. Evans RG, Ince C, Joles JA, Smith DW, May CN, O'Connor PM, Gardiner BS. Hemodynamic influences on kidney oxygenation: clinical implications of integrative physiology. Clin Exp Pharmcol Physiol 40: 106-122, 2013.
16. Grantham JJ, Torres V, Chapman AB, Guay Woodford LM, Bae KT, King B, Wetzel L, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman G, Meyers CM, Zhang X, Zhu F, Miler JP. Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006.
17. Harrap SB, Davies DL, Macnicol AM, Dominiczak AF, Fraser R, Wright AF, Watson ML, Briggs JD. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 40: 501-508, 1991.
18. Hering D, Zdrojewski Z, Krol E, Kar T, Kucharska W, Somers VK, Rutkowski B, Narkiewicz K. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens 25: 157-161, 2007.
19. Hildreth CM, Kandukuri DS, Goodchild AK, Phillips JK. Temporal development of baroreceptor dysfunction in a rodent model of chronic kidney disease. Clin Exp Pharmacol Physiol 40: 458-465, 2014.
20. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 13: 2384-2398, 2002.
21. King B, Torres V, Brummer M, Chapman A, Bae K, Glockner J, Arya K, Felmlee J, Grantham J, Guay Woodford L, Bennett W, Klahr S, Hirschman G, Kimmel P, Thompson P, Miller JP. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 64: 2214- 2221, 2003.
22. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427-2433, 2001.
23. Leong CL, Anderson WP, O'Connor PM, Evans RG. Evidence that renal arterial-venous oxygen shunting contributes to dynamic regulation of renal oxygenation. Am J Physiol Renal Physiol 292: F1726-F1733, 2007.
24. Liang G, Li Q, Yang Y, Kokame K, Kikuchi T, Wu G, Chen X. Polycystin-2 is regulated by endoplasmic reticulum-associated degradation. Hum Mol Genet 17: 1109-1119, 2008.
25. Liu B, Li C, Liu Z, Dai Z, Tao Y. Increasing extracellular matrix collagen level and MMP activity induces cyst development in polycystic kidney disease. BMC Nephrol 13: 109-116, 2012.
26. Loghman-Adham M, Soto CE, Inagami T, Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 287: F775-F788, 2004.
27. Maser R, Vassmer D, Magenheimer B, Calvet J. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol 13: 991-999, 2002.
28. McCooke JK, Appels R, Barrero RA, Ding A, Oximek-Kulik Je, Bellgard MI, Morahan G, Phillips JK. A novel mutation causing nephronophthisis in the Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8. BMC Genomics 13: 393-409, 2012.
29. Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong P, Gansevoort R. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5: 1091-1098, 2010.
30. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6: 7-13, 2011.
31. Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol 17: 317-326, 2013.
32. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Sem Nephrol 24: 354-365, 2004.
33. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006.
34. O'Connor PM, Kett MM, Anderson WP, Evans RG. Renal medullary tissue oxygenation is dependent on both cortical and medullary blood flow. Am J Physiol Renal Physiol 290: F688-F694, 2006.
35. Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, Neilson EG. Progressive renal fibrosis in murine polysytic kidney disease: An immunohistochemical observation. Kidney Int 58: 587-597, 2000.
36. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 46: 1153-1160, 2003.
37. Persson P, Hansell P, Palm F. NADPH oxidase inhibition reduces tubular sodium transport and improves kidney oxygenation in diabetes. Am J Physiol Regul Integr Comp Physiol 302: R1443-R1449, 2012.
38. Phillips J, Hopwood D, Loxley R, Ghatora K, Coombes J, Tan Y, Harrison J, McKitrick D, Holobotvskyy V, Arnolda L, Rangan G. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press Res 30: 129-144, 2007.
39. Ploth DW, Schnermann J, Dahlheim H, Hermle M, Schmidmeier E. Autoregulation and tubuloglomerular feedback in normotensive and hypertensive rats. Kidney Int 12: 253-267, 1977.
40. Priolo C, Henske E. Metabolic reprogramming in polycystic kidney disease. Nature Med 19: 407-409, 2013.
41. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66: 2576-2583, 2006.
42. Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song X, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nature Med 19: 488-493, 2013.
43. Salman IMM HC, Ameer OZ, Phillips JK. Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. Hypertension 63: 804-810, 2014.
44. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 282: R335-R342, 2002.
45. Schwensen KG, Burgess JS, Graf NS, Alexander SI, Harris DC, Phillips JK, Rangan GK. Early cyst growth is associated with the increased nuclear expression of cyclin D1/Rb protein in an autosomalrecessive polycystic kidney disease rat model. Nephron Exp Nephrol 117: e93-e103, 2011.
46. Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens 21: 189-194, 2012.
47. Tanner GA, Tanner JA. Citrate therapy for polycystic kidney disease in rats. Kidney Int 58: 1859-1869, 2000.
48. Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, Faubel S, Schrier RW, Edelstein CL. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 72: 1358-1366, 2007.
49. Thurau K. Renal hemodynamics. Am J Med 36: 698-719, 1964.
50. Torres V, King B, Chapman A, Brummer M, Bae K, Glockner J, Arya K, Risk D, Felmlee J, Grantham J, Guay Woodford L, Bennett W, Klahr S, Meyers C, Zhang X, Thompson P, Miller JP. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2: 112-120, 2007.
51. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
52. Wei W, Popov V, Walocha JA, Wen J, Bello Reuss E. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 70: 1261-1268, 2006.
53. Welch WJ, Mendoca M, Aslam S, Wilcox CS. Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension 41: 692-696, 2003.
54. Xu R, Franchi F, Miller B, Crane JA, Peterson KM, Psaltis PJ, Harris PC, Lerman LO, Rodriguez-Porcel M. Polycystic kidneys have decreased vascular density: A micro-CT study. Microcirculation 20: 183- 189, 2013.
55. Young LS, Regan MC, Sweeney P, Barry KM, Ryan MP, Fitzpatrick JM. Changes in regional renal blood flow after unilateral nephrectomy using the techniques of autoradiography and microautoradiography. J Urol 160: 926-931, 1998.
56. Zafar I, Tao Y, Falk S, Mc Fann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 293: F854-F859, 2007.